Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 431,040 |
|
|||||
| News | - | ||||||
| Day High | 10.31 | Low High |
|||||
| Day Low | 9.79 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Shattuck Labs Inc | STTK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.18 | 1.80% | 10.20 | 19:46:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.00 | 9.79 | 10.31 | 10.13 | 10.02 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,949 | 431,040 | $ 10.06 | $ 4,338,073 | - | 1.3301 - 11.11 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:46:51 | 8 | $ 10.28 | USD |
Shattuck Labs Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 480.92M | 47.47M | - | 1.66M | -87.3M | -1.84 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Shattuck Labs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STTK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.82 | 10.31 | 8.85 | 9.60 | 264,349 | 0.38 | 3.87% |
| 1 Month | 9.54 | 10.31 | 8.56 | 9.34 | 252,257 | 0.66 | 6.92% |
| 3 Months | 10.01 | 11.11 | 8.06 | 9.24 | 324,411 | 0.19 | 1.90% |
| 6 Months | 1.54 | 11.11 | 1.36 | 6.32 | 972,097 | 8.66 | 562.34% |
| 1 Year | 2.90 | 11.11 | 1.3301 | 6.20 | 501,957 | 7.30 | 251.72% |
| 3 Years | 29.63 | 38.90 | 1.3301 | 8.40 | 281,005 | -19.43 | -65.58% |
| 5 Years | 18.61 | 60.5162 | 1.3301 | 11.13 | 266,038 | -8.41 | -45.19% |
Shattuck Labs Description
| Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. |
